sc291
Generic: HIP-modified allogeneic CD19-directed CAR T cell
sc291: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Sana Biotechnology, Inc. (SANA) | Phase 1 |
Clinical Trials (1)
A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)
Frequently asked questions
Who is developing sc291?
sc291 is being developed by Sana Biotechnology, Inc..
How many clinical trials involve sc291?
BioSniper tracks 1 clinical trial involving sc291.
Get deeper analysis on sc291
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis